The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response
Abstract
OBJECTIVE: Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD). METHOD: In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind conditions. RESULTS: The response rates for both atomoxetine (45%) and methylphenidate (56%) were markedly superior to that for placebo (24%), but the response to osmotically released methylphenidate was superior to that for atomoxetine. Each medication was well tolerated, with completion rates and discontinuations for adverse events not significantly different from those for placebo. Of the 70 subjects who did not respond to methylphenidate, 30 (43%) subsequently responded to atomoxetine. Likewise, 29 (42%) of the 69 patients who did not respond to atomoxetine had previously responded to osmotically released methylphenidate. CONCLUSION: Response was significantly greater with osmotically released methylphenidate than with atomoxetine. One-third of patients who received methylphenidate followed by atomoxetine responded better to one or the other, suggesting that there may be preferential responders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stimulant medications have an effect size of around 1.0 (effect size = [treatment M − control M)/control SD]) for the treatment of ADHD.98”
From Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019) · cites this paper as [98]
In the citing paper
“These shared and distinct substrates may delineate a novel therapeutic target for effective interventions and could account for different therapeutic responses to stimulants and nonstimulants among individuals with ADHD”
From Overlapping and differential neuropharmacological mechanisms of stimulants and nonstimulants for attention-deficit/hyperactivity disorder: A comparative neuroimaging analysis (2024) · cites this paper as Newcorn et al., 2008
In the citing paper
“approximately 56% of ADHD cases may achieve clinical improvement with stimulants, while 45% of cases achieve so with non-stimulants (Mechler et al., 2022; Newcorn et al., 2008).”
From Overlapping and differential neuropharmacological mechanisms of stimulants and nonstimulants for attention-deficit/hyperactivity disorder: A comparative neuroimaging analysis (2024) · cites this paper as Newcorn et al., 2008
In the citing paper
“Lower frequencies of insomnia and higher frequencies of somnolence with atomoxetine than with long-acting stimulants have been reported as TEAEs in randomized, double-blind, parallel-group efficacy studies (Dittmann et al. 2013; Newcorn et al. 2008).”
From Associations of sleep disturbance with ADHD: implications for treatment (2015) · cites this paper as Newcorn et al. 2008
In the citing paper
“In contrast, one large (n = 516), double-blind, placebo-controlled, crossover study found that the proportions of stimulant-naïve children with ADHD who responded to osmotic-release oral system MPH (OROS-MPH) and ATX (64 and 57 %, respectively; effect sizes relative to placebo based on ADHD-RS-IV total score, 1.0 and 0.9) were higher than among those who had previously been treated with a psychost”
In the citing paper
“Nine randomized trials comparing methylphenidate and atomoxetine, with a total of 2762 participants were included.”
In the citing paper
“Two trials excluded participants with previous poor response to methylphenidate, a design feature which would have favoured methylphenidate [27,28].”
In the citing paper
“The outcome in three of these trials favoured atomoxetine suggesting that higher doses of atomoxetine administered twice daily may be more effective.”
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
(1998) · Cited by 2,026
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Conners' rating scales-revised : technical manual
Conners, C. K. (1997) · Medical Entomology and Zoology · Cited by 1,004
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Self-citationAttention-Deficit, S. O., & Disorder, H. (2001) · Pediatrics · doi:10.1542/peds.108.4.1033 · Cited by 636
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Self-citationKelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Self-citationSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333
Self-citation
Flagged first, then by citations
Research works printed but not linked: 7
- Jadad AR, 1999, Md
- Kaufman J, 1996, Ryan N: Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL)
- World Medical Association, 2000, France
- Gao H, 2006, Scientific Proceedings of the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 201
- Landgraf JM, 1996, Abetz L
- International Conference, 1998, Fed Regist, 63, 49583
- Newcorn JH, 2004, Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 48
Cited by
Sorted by citations
Items 101–111 of 111
Zeiner, P., Gjevik, E., & Weidle, B. (2011) · Acta Paediatrica · doi:10.1111/j.1651-2227.2011.02263.x · Cited by 36
Martenyi, F., Zavadenko, N. N., Jarkova, N. B., Yarosh, A. A., Soldatenkova, V. O., Bardenstein, L. M., Kozlova, I. A., Neznanov, N. G., Maslova, O. I., Petrukhin, A. S., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0042-7 · Cited by 36
Toward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33
Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†
Garnock-Jones, K. P., & Keating, G. M. (2010) · CNS Drugs · doi:10.2165/11203670-000000000-00000 · Cited by 32
Changes in Emotions Related to Medication Used to Treat ADHD. Part I: Literature Review
Manos, M. J., Brams, M., Childress, A. C., Findling, R. L., López, F. A., & Jensen, P. S. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710381230 · Cited by 28
Whalen, C. K., Henker, B., Ishikawa, S. S., Emmerson, N. A., Swindle, R., & Johnston, J. A. (2010) · Journal of Attention Disorders · doi:10.1177/1087054708325118 · Cited by 15
Lilja, M. M., Sandblom, E., Lichtenstein, P., Serlachius, E., Hellner, C., Bhagia, J., & Halldner, L. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09424-2 · Cited by 14
Brams, M., Childress, A. C., Greenbaum, M., Yu, M., Yan, B., Jaffee, M., & Robertson, B. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0053 · Cited by 12
Luan, R., Mu, Z., Yue, F., & He, S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00229 · Cited by 11
Hammerness, P., Doyle, R., Kotarski, M., Georgiopoulos, A., Joshi, G., Zeitlin, S., & Biederman, J. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0017-8 · Cited by 8
Pan, N., Ma, T., Liu, Y., Zhang, S., Hu, S., Shekara, A., Cao, H., Gong, Q., & Chen, Y. (2024) · Psychological Medicine · doi:10.1017/s003329172400285x · Cited by 7
“Regarding various treatment responses among individuals, investigation of their neuropharmacological bases that may facilitate the selection of preferential responders becomes indispensable (Newcorn et al., 2008).”
Metadata
- Authors
- Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group
- Affiliations
- Mount Sinai Hospital (US)
- Venue
- American Journal of Psychiatry
- Published
- 2008-06
- Volume
- 165
- Issue
- 6
- Pages
- 721-730
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2130386846
- Cited by
- 336
- References
- 23
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 14 · 2018: 9 · 2017: 21 · 2016: 20 · 2015: 33 · 2014: 32 · 2013: 20 · 2012: 30
- FWCI
- 22.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, non-stimulant medication, norepinephrine reuptake inhibitors, treatment response, differential drug response, children and adolescents, ADHD Rating Scale
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Central Nervous System Stimulants, Child, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Methylphenidate, Personality Assessment, Propylamines, Treatment Outcome, Cross-Over Studies, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
